Hot Features
プレミアム
Geron Corp (GERN)
NASDAQ
登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a ... Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. 詳細を表示
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a fireside chat at the Stifel 2024...
RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma’s synthetic...
Geron received $250 million in gross proceeds at closing, with access to an additional $125 million in debt Strengthens balance sheet to support the commercial launch of RYTELO™ in the U.S. and...
Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of sales Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty...
New analyses from the IMerge clinical trial suggest that imetelstat demonstrates clinical activity in patients with lower-risk MDS with transfusion-dependent anemia regardless of prior therapy...
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 680,220 shares of Geron...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.51 | -12.1140142518 | 4.21 | 4.33 | 3.63 | 10778477 | 3.98571339 | CS |
| 4 | -0.36 | -8.86699507389 | 4.06 | 4.5 | 3.63 | 9432983 | 4.12232426 | CS |
| 12 | -0.82 | -18.1415929204 | 4.52 | 4.825 | 3.63 | 8459191 | 4.31224965 | CS |
| 26 | -0.05 | -1.33333333333 | 3.75 | 5.34 | 3.23 | 10048022 | 4.42358484 | CS |
| 52 | 1.78 | 92.7083333333 | 1.92 | 5.34 | 1.64 | 9806409 | 3.60575569 | CS |
| 156 | 2.11 | 132.704402516 | 1.59 | 5.34 | 0.9899 | 6346389 | 3.01509665 | CS |
| 260 | 2.33 | 170.072992701 | 1.37 | 5.34 | 0.75 | 5099478 | 2.67417842 | CS |
Spike5
21時間前
Stumblebum
5日前
Spike5
5日前
learningcurve2020
1週前
learningcurve2020
1週前
learningcurve2020
1週前
Stumblebum
2週前
Stumblebum
2週前
Spike5
2週前
Stumblebum
2週前
Spike5
2週前
learningcurve2020
3週前
big bambino
3週前
Stumblebum
3週前
big bambino
3週前
Spike5
4週前
learningcurve2020
4週前
big bambino
4週前
Stumblebum
4週前
big bambino
4週前
big bambino
4週前
Stumblebum
4週前
learningcurve2020
4週前
seward
4週前
Stumblebum
1月前
Spike5
1月前
Stumblebum
1月前
Stumblebum
1月前
Spike5
1月前
Spike5
1月前
Spike5
1月前
Spike5
1月前
learningcurve2020
1月前
Spike5
1月前
big bambino
1月前
attilathehunt
2月前
big bambino
2月前
Stumblebum
2月前
Stumblebum
2月前
luckygm
2月前
Spike5
2月前
Spike5
2月前
Stumblebum
2月前
Stumblebum
2月前
attilathehunt
2月前
big bambino
2月前
big bambino
2月前
Stumblebum
2月前
learningcurve2020
2月前
big bambino
2月前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
